Enanta Pharmaceuticals (ENTA) Shares Up 12%

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) shares shot up 12% during trading on Thursday . The company traded as high as $54.83 and last traded at $53.98. 632,300 shares were traded during trading, an increase of 224% from the average session volume of 195,288 shares. The stock had previously closed at $48.20.

A number of research firms have recently commented on ENTA. Royal Bank of Canada began coverage on Enanta Pharmaceuticals in a research note on Thursday, September 14th. They set an “outperform” rating on the stock. Zacks Investment Research cut Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, October 4th. JMP Securities upped their target price on Enanta Pharmaceuticals from $40.00 to $53.00 in a research note on Wednesday, October 4th. Finally, TheStreet raised Enanta Pharmaceuticals from a “c+” rating to a “b-” rating in a research note on Wednesday. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $46.25.

The stock has a market capitalization of $1,031.85, a price-to-earnings ratio of 61.31 and a beta of 0.64.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings results on Monday, November 20th. The biotechnology company reported $1.86 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.13 by ($0.27). The firm had revenue of $75.93 million during the quarter, compared to analysts’ expectations of $73.80 million. Enanta Pharmaceuticals had a net margin of 17.23% and a return on equity of 6.46%. The firm’s revenue for the quarter was up 491.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.09) EPS. research analysts predict that Enanta Pharmaceuticals Inc will post -1.57 EPS for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in ENTA. Teachers Advisors LLC boosted its holdings in shares of Enanta Pharmaceuticals by 2.9% in the first quarter. Teachers Advisors LLC now owns 25,182 shares of the biotechnology company’s stock valued at $776,000 after purchasing an additional 700 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Enanta Pharmaceuticals by 7.2% in the first quarter. Vanguard Group Inc. now owns 792,165 shares of the biotechnology company’s stock valued at $24,399,000 after purchasing an additional 53,007 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Enanta Pharmaceuticals by 129.7% in the first quarter. Dimensional Fund Advisors LP now owns 413,089 shares of the biotechnology company’s stock valued at $12,723,000 after purchasing an additional 233,265 shares during the period. Schwab Charles Investment Management Inc. boosted its holdings in shares of Enanta Pharmaceuticals by 5.4% in the first quarter. Schwab Charles Investment Management Inc. now owns 53,312 shares of the biotechnology company’s stock valued at $1,643,000 after purchasing an additional 2,736 shares during the period. Finally, Capstone Asset Management Co. purchased a new stake in shares of Enanta Pharmaceuticals in the second quarter valued at approximately $212,000. Hedge funds and other institutional investors own 66.97% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was first posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of international copyright laws. The original version of this piece of content can be accessed at https://www.com-unik.info/2017/12/16/enanta-pharmaceuticals-enta-shares-up-12.html.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

What are top analysts saying about Enanta Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Enanta Pharmaceuticals and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit